Press Releases

Date Title and Summary Additional Formats
Toggle Summary Radius to Host Investor Day on June 8, 2018
Advancing Treatment Care for Osteoporosis
View HTML
Toggle Summary Radius Health to Present at the Bank of America Merrill Lynch 2018 Annual Healthcare Conference
WALTHAM, Mass., May 11, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that Jesper Høiland, President and Chief Executive officer and Pepe Carmona, Senior Vice President and Chief Financial Officer of the Company, will present a corporate update at the Bank of America
View HTML
Toggle Summary Radius Health Reports First Quarter 2018 Financial and Operating Results and Provides Business Update
First quarter 2018 TYMLOS® sales increase to $14.5 million, a 90% increase  over the fourth quarter of 2017 TYMLOS captured on average 13% of the U.S. anabolic osteoporosis market and 31% of new anabolic patient starts in the quarter Radius targets TYMLOS capturing on average 19-21% of the U.S.
View HTML
Toggle Summary Radius Health to Announce First Quarter 2018 Financial Results, Host Conference Call and Live Webcast on May 10, 2018
WALTHAM, Mass., April 24, 2018 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its first quarter financial results on Thursday, May 10, 2018. The Company will host a conference call and live audio webcast at 8:00 a.m.
View HTML
Toggle Summary Radius Health Initiates Phase 3 Clinical Trial of Abaloparatide Injection for the Treatment of Male Osteoporosis
Bridging study will evaluate change in spine bone mineral density (BMD) at 12 months compared with placebo
View HTML
Toggle Summary Radius Health Provides Update on CHMP Opinion for Abaloparatide-SC
WALTHAM, Mass., March 22, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced that
View HTML
Toggle Summary Radius Health Presents Positive Data for the ACTIVExtend BMD Responder Analysis for TYMLOS™ (abaloparatide) Injection at ENDO 2018 Annual Meeting
WALTHAM, Mass., March 17, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today presented results
View HTML
Toggle Summary Radius Health to Present at ENDO 2018 Including Results of the ACTIVExtend BMD Responder Analysis for TYMLOS™ (abaloparatide) Injection
WALTHAM, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced two
View HTML
Toggle Summary Radius Health to Present at the Cowen 38th Annual Health Care Conference
WALTHAM, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that Jesper Høiland, President and CEO of the Company, will present a corporate update at Cowen's 38th Annual Health Care Conference on Monday, March 12, 2018.  Information on the presentation is as
View HTML
Toggle Summary Radius Health Reports Fourth Quarter and Full Year 2017 Financial and Operating Results and Provides Business Update
TYMLOS ™ sales show accelerating market share growth, capturing approximately 32% of osteoporosis patients new to anabolic therapy Abaloparatide patch program advances with FDA alignment on regulatory pathway  and completion of commercial supply agreement with 3M Company Global regulatory
View HTML